



Supplementary Figure 5. Subgroup analysis of total treatments. (A) Annual number of each treatment performed: surgical resection (open and laparoscopic approaches), local ablation (RFA, MWA, and cryoablation), transarterial therapy (cTACE, DEB-TACE, TARE, and others), and systemic therapy (sorafenib, lenvatinib, and atezolizumab-bevacizumab). (B) Annual percentages of each treatment: surgical resection (open and laparoscopic approaches), local ablation (RFA, MWA, and cryoablation), transarterial therapy (cTACE, DEB-TACE, TARE, and others), and systemic therapy (sorafenib, lenvatinib, and atezolizumab-bevacizumab). RFA, radiofrequency ablation; MWA, microwave ablation; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; TARE, transarterial radioembolization.